ArticleReports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology2025
Hypofractionated radiotherapy for glioblastoma: correlation with prognostic factors and survival outcomes.
Article in Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The purpose was to evaluate the efficacy of hypofractionated radiotherapy (HFRT) followed by conventional fractionated radiotherapy (CFRT) in glioblastoma multiforme (GBM) patients and identify prognostic factors. Materials and methods: We conducted a retrospective analysis of 120 GBM patients treated postoperatively between 2010 and 2017 with HFRT (30 Gy in 3 Gy fractions) followed by CFRT (24 Gy in 2 Gy fractions), for a total dose of 60 Gy. All patients received concurrent and adjuvant temozolomide (TMZ). Results: Median age was 62.5 years. Median overall survival (OS) was 11.3 months; 1-, 2-, and 3-year survival rates were 43.3%, 16.1%, and 4.6%, respectively. Full dose completion correlated with improved OS (12.2 Conclusions: HFRT followed by CFRT with TMZ is an effective alternative to standard CFRT in patients with subtotal or partial resection. Age and tumor volume are independent prognostic factors for overall survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.